Despite positive clinical data, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable difficulty from managed care entities. These insurers are frequently erecting obstacles to access, such as steep cost restrictions and PA that